Tuesday

Hillstream BioPharma to Present at the 12th Annual LDMicro 12th Main Event

Chester, NJ – December 3, 2019 — Hillstream BioPharma Inc. (“Hillstream”) today announced that Chief Executive Officer, Randy Milby, will be presenting and meeting with investors at the 12th Annual LD Micro Annual Main Event Conference being held December 10-12, 2019 in Bel Air, CA. Details on Hillstream’s presentation are as follows:

Event: 12th Annual LD Micro Main Event Conference
Date: Tuesday, December 10, 2019
Time: 9:20am PT
Room: Track 4
Location: Luxe Sunset Boulevard Hotel

(more…)

Tuesday

Hillstream BioPharma Announces Kwok-Kin Wong, MD, PhD as New Member to Scientific Advisory Board

Expertise in Small Cell Lung Cancer Supports Key Pipeline Drug – HSB: 1216

Chester, New Jersey, November 19, 2019 – Hillstream BioPharma Inc. (“Hillstream”) today announced the addition of clinician-scientist Kwok-Kin Wong, MD, PhD to Hillstream’s Scientific Advisory Board.

Dr. Wong brings a wealth of experience from being a professor of oncology to conducting leading-edge research in lung cancer. Dr. Wong is the Chief of Hematology and Medical Oncology at The Perlmutter Cancer Center at NYU Langone Medical Center. During his distinguished career, Dr. Wong served in various investigative and leadership roles at Dana-Farber Cancer Institute, Brigham & Women’s Hospital, and Harvard Medical School. Dr. Wong’s work has been published in over 250 scientific publications, and his world-renowned research has provided new insight into genetic and environmental causes of lung cancer, enabling novel lung cancer therapies. Throughout his career, Dr. Wong has received numerous honors and accolades including: the Howard Hughes Physician Scientist Fellowship, the Dunkin Donuts Rising Star Research Grant Award, the AACR Team Science Award, and the Anne Murnick Cogan and David H. Cogan Professor of Oncology. Currently, Dr. Wong continues his investigative pursuits, in to developing novel therapeutic strategies for small cell and non-small cell lung cancer. Dr. Wong received both his PhD and MD from Columbia University, completed his residency at Massachusetts General Hospital, and was a fellow at the Dana-Farber Cancer Institute. (more…)

Monday

Hillstream BioPharma Announces Collaboration with Ardena to Support QUATRAMER Manufacturing

Highlighted in BioWorld

Alignment Reinforces Hillstream BioPharma’s Strategy to
Partner with Top-Tier Firms

Chester, NJ – November 4, 2019 – Hillstream BioPharma, Inc. (“Hillstream”) today announced a collaboration with Ardena to secure manufacturing feasibility and capacity for Hillstream’s QUATRAMER portfolio. This includes HSB-1216, a novel formulation of salinomycin encapsulated within the QUATRAMER technology, a potent cancer stem cell inhibitor with initial indications for small cell lung cancer. (more…)

Thursday

Hillstream BioPharma Announces Renewal of CRADA with National Center for Advancing Translational Sciences for Use of QUATRAMER™ Drug Delivery Technology with HDAC6-PI3Kδ Dual Inhibitor for AML

Chester, NJ – October 10, 2019 — Hillstream BioPharma Inc. (“Hillstream”) today announced the renewal of a Cooperative Research and Development Agreement (CRADA) with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH). The agreement enables NCATS’s use of the company’s QUATRAMER drug delivery technology.  This technology will be used to develop formulations of HDAC6-PI3Kδ dual inhibitors for the treatment of rare cancers, including acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL).

Studies have shown that by disrupting multiple compensatory cyto-protective pathways, HDAC6-PI3Kδ dual inhibitors might have potential therapeutic value.  The primary objective of the study is encapsulation of NCATS developed HDAC6-PI3Kδ dual inhibitors into Hillstream’s proprietary, nanoparticle tumor infiltrating QUATRAMER suspension to assist with enhanced and safer delivery into malignant cells. (more…)

Tuesday

Hillstream BioPharma Acquires Key Assets to Portfolio Including QUATRAMER Drug Delivery Technology Platform and Key Immuno-Oncology Compounds

Acquisition Positions Hillstream as a Diversified Biotechnology Company Developing Novel, IND-Ready
Immuno-Oncology Treatments for Orphan Tumors with Devastating and Unmet Need

Chester, NJ — September 10, 2019 – Hillstream BioPharma Inc. (“Hillstream”) today announced the acquisition of key immuno-oncology (IO) assets from privately held NanoProteagen, Inc., including its proprietary drug delivery platform QUATRAMER, a proprietary, non-viral tumor infiltrating enhanced injectable suspension.

The company believes this acquisition solidifies its position as a novel drug delivery platform company, as it includes several immuno-oncology drug candidates.  In addition to the QUATRAMER delivery platform, which forms the basis of the entire portfolio, Hillstream has acquired and is developing HSB-114, an immunotherapeutic agent delivering the human tumor necrosis factor-alpha (TNF-α) gene.  Hillstream is progressing towards a rapid IND filing process and plans to initiate a clinical trial in advanced, metastatic soft tissue sarcomas (STS).

“With the addition of QUATRAMER as our key platform, we are now poised to enter the IO space with a novel technology that we believe may provide a non-viral tumor specific delivery vehicle of cytokines with high efficacy in tumors with too narrow a therapeutic index for clinical feasibility, including TNF-alpha and others,” stated Randy Milby, chief executive officer of Hillstream. “With the preclinical success we’ve had to date with HSB-114, we anticipate a rapid progression toward an IND and initiation of Phase 1b/2a trials.  We look forward to sharing our progress of these and future milestones with current and potential shareholders.” (more…)

Monday

Hillstream BioPharma Announces Participation at the 2019 ASCO Annual Meeting, May 31-June 4, 2019, McCormick Place, Chicago, IL

Chester, N.J., May 20, 2019 – Hillstream BioPharma Inc. (“Hillstream”), a development-stage company advancing improved therapies for patients with cancer, today announced it intends to have a presence at the 2019 ASCO Annual Meeting, May 31-June 4, 2019 at McCormick Place, Chicago, IL.

Event:      2019 ASCO Annual Meeting
Date:        Friday, May 31, 2019 – Tuesday, June 4, 2019
Time:        8:00am – 6:00pm CDT
Location:  McCormick Place, Chicago, IL (more…)

Friday

Interview with Randy Milby, CEO

This is the second post in an interview series with CEOs of small- to mid-cap companies, in which we ask them about products in development. Here we talk with Randy Milby, Chief Executive Officer at Hillstream BioPharma, Inc, Chester, New Jersey (https://www.hillstreambio.com).

 RANDY MILBY: I’ll start with how I founded the company, Hillstream Biopharma. Until recently, the end of last September, I was the CEO of CorMedix, which is a publicly traded company on the New York Stock Exchange. While I was at CorMedix, there was a paper that came out of Germany that said that taurolidine combined with vincristine, an anticancer drug, had a synergistic effect on tumors. Taurolidine is a cornerstone antimicrobial compound for CorMedix. It’s not an antibiotic but it has antibacterial effects, and some antifungal effects, and it’s one of the active components of Neutrolin®, which is in a phase 3 study. Neutrolin® is an anti-microbial drug developed as a preventative solution to decrease the threat of infection and blood clots (thrombosis), thereby keeping central venous catheters (CVCs) operating safely and efficiently. (more…)